Snapshot from Nov 22, 2026 at 07:00 UTC. For live data and tracking: View Live
Entity

F. Hoffmann-La Roche — Genentech

Tracked across 23 events · 201 articles · First seen Dec 19, 2025 · Last active Sep 24, 2026

Sentiment
18
Attention
6
Events
23
Relationships
4
Live sentiment trends, attention charts, and prominence tracking available on the Ergen Dashboard
6 75
Tech
Impact: As a member of the Roche Group, F. Hoffmann-La Roche — Genentech>>> developed giredestrant and had its New Drug Application accepted by the United States — Food and Drug Administration>>> for priority review, indicating potential for a new standard-of-care in breast cancer treatment.
Jun 02, 2026 · 6 articles
6 75
Tech
Impact: F. Hoffmann-La Roche — Genentech announced positive Phase II clinical trial data for its obesity drugs, enicepatide and petrelintide, which could significantly strengthen its product portfolio and market position in the obesity treatment sector. The company is advancing both drugs to Phase III development and initiating a combination trial.
May 27, 2026 · 19 articles
2 20
Business
Impact: F. Hoffmann-La Roche — Genentech is the primary actor, celebrating the topping out of its new $2 billion facility in United States — Holly Springs, which will produce metabolic treatments and strengthen its U.S. manufacturing footprint.
Aug 18, 2026 · 6 articles
4 40
Tech
F. Hoffmann-La Roche — Genentech, a member of the Roche Group, and its partner Ionis Pharmaceuticals announced positive prespecified interim results from the ongoing Phase III IMAgINATION study evaluating investigational sefaxersen in adults with primary…
Impact: F. Hoffmann-La Roche — Genentech is the lead sponsor of the IMAgINATION study and announced the positive interim results, strengthening its immunology pipeline and near-term commercial prospects in IgAN.
Sep 23, 2026 · 6 articles
4 70
Business
Impact: F. Hoffmann-La Roche — Genentech gains exclusive rights to a promising obesity therapy, expanding its pipeline. The deal involves significant financial commitment but offers potential long-term returns.
Jul 20, 2026 · 7 articles
2 30
Business
Impact: F. Hoffmann-La Roche — Genentech gains access to MaxCyte's platform technologies to advance its cell therapy pipeline, potentially accelerating development timelines. The partnership is a strategic move to strengthen its cell therapy capabilities.
Jul 21, 2026 · 6 articles
6 20
Regulatory
Impact: F. Hoffmann-La Roche — Genentech, Roche's US unit, is one of the nine major pharmaceutical companies that signed deals with the Donald Trump administration to reduce drug prices.
Dec 19, 2025 · 7 articles
4 20
Regulatory
Impact: F. Hoffmann-La Roche — Genentech's Tecentriq (atezolizumab) is the therapy guided by Signatera in this CDx application. Positive trial data could boost Tecentriq's use in adjuvant bladder cancer.
Aug 05, 2026 · 7 articles
3 30
Tech
Impact: Provided funding and data from the ORATORIO trial; the method could help evaluate Ocrelizumab's effect on cortical lesions.
Jul 07, 2026 · 6 articles
2 5
Regulatory
Natera announced that its Signatera test received regulatory approval from Japan's Japan — Pharmaceuticals and Medical Devices Agency as a companion diagnostic in muscle-invasive bladder cancer. The approval supports the use of Signatera to guide…
Impact: F. Hoffmann-La Roche — Genentech's atezolizumab (Tecentriq) is the therapy that Signatera guides, so the approval supports companion diagnostic use alongside its drug in Japan.
Sep 22, 2026 · 6 articles
2 10
Regulatory
Roche announced on 10 September 2026 that the United States — Food and Drug Administration has granted Priority Review to a supplemental Biologics License Application for Enspryng (satralizumab) for the treatment of myelin oligodendrocyte glycoprotein…
Impact: F. Hoffmann-La Roche — Genentech, Roche's fully owned U.S. subsidiary, would commercialize Enspryng in the United States if the MOGAD indication is approved.
Sep 09, 2026 · 6 articles
4 0
Business
Impact: F. Hoffmann-La Roche — Genentech has licensed MiNK Therapeutics' STAC-BBB platform for neurological targets, indicating a past business relationship that could be affected by Sangamo's strategic review.
Jun 08, 2026 · 7 articles
3 0
Tech
Impact: One of the funders; may be associated with lung cancer treatments.
Jul 13, 2026 · 6 articles
4 10
Regulatory
Impact: F. Hoffmann-La Roche — Genentech, as a partner of ArkBio, may benefit from the progress of ziresovir through their strategic collaboration.
Jul 20, 2026 · 6 articles
4 10
Tech
Impact: F. Hoffmann-La Roche — Genentech originally licensed paxalisib to Kazia; the drug's progress may reflect positively on F. Hoffmann-La Roche — Genentech's early research, but F. Hoffmann-La Roche — Genentech has no direct involvement in this event.
Jul 20, 2026 · 7 articles
4 5
Tech
Anthropic has quietly established a wet lab in the San Francisco Bay Area to conduct physical biology experiments, moving beyond computer-based in silico research into hands-on drug science. The lab's existence was confirmed by Eric…
Impact: Receives AI services from Anthropic as part of its pharmaceutical partnerships.
Sep 18, 2026 · 22 articles
2 0
Business
Impact: Gavin Barnard previously held senior leadership roles at F. Hoffmann-La Roche — Genentech, contributing to his extensive biopharma experience.
Apr 16, 2026 · 6 articles
3 -10
Business
Impact: F. Hoffmann-La Roche — Genentech's Ocrevus faces potential biosimilar competition, which may erode market share.
Jul 09, 2026 · 14 articles
1 0
Business
Impact: F. Hoffmann-La Roche — Genentech is mentioned as Borellini's former employer; not directly affected by this event.
Jul 13, 2026 · 6 articles
0 0
Business
Impact: F. Hoffmann-La Roche — Genentech is mentioned as a former employer of Sunita Parasuraman, providing background but not directly affected.
Jul 20, 2026 · 6 articles
2 0
Business
Impact: F. Hoffmann-La Roche — Genentech licensed paxalisib to Kazia in 2016. The offering funds further development of this asset, potentially leading to future royalties or milestones for F. Hoffmann-La Roche — Genentech.
Jul 20, 2026 · 22 articles
4 0
Tech
Apr 17, 2026 · 10 articles
6 0
Tech
Impact: F. Hoffmann-La Roche — Genentech is a fully owned subsidiary of Roche in the United States. This event does not directly impact F. Hoffmann-La Roche — Genentech.
Jun 29, 2026 · 7 articles
Roche ↔ F. Hoffmann-La Roche — Genentech
Roche ↔ F. Hoffmann-La Roche — Genentech
United States — Food and Drug Administration ↔ F. Hoffmann-La Roche — Genentech
United States — Food and Drug Administration ↔ F. Hoffmann-La Roche — Genentech
ERGEN INTELLIGENCE
Track F. Hoffmann-La Roche — Genentech live

Set up alerts, explore relationships, view sentiment trends, and monitor how events impact this entity in real time.

Open Dashboard

About Ergen

Ergen is a news intelligence platform that converts raw news articles into structured data. It tracks events, entities, and the relationships between them, with sentiment and attention metrics derived from thousands of articles. Pages on this site are daily static snapshots from the platform's live database. For real-time tracking, search, and alerts, the full dashboard is at app.ergen.ai.